AML is/was the fastest pathway to market. I think it's unlikely they abandon those plans. They only caveat being that with the delays caused by IV formulation there may be a faster pathway to market via cardioprotection.
Would be interesting to know what was discussed with the FDA last November.
General Comments / Chat, page-7156
-
- There are more pages in this discussion • 4,867 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
0.085(5.80%) |
Mkt cap ! $264.2M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.55 | $1.49 | $246.4K | 163.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $1.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.55 | 5483 | 2 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |